The mission of the Case CCC Tissue Resources Core Facility is to coordinate five services: tissue procurement, biorepository, tissue processing, histology, and immunohistochemistry (IHC). Tissue procurement prospectively collects, prepares, and distributes human tissue samples and associated deidentified data directly to investigators and/or to the biorepository, tissue processing, histology, and IHC components. Within these components, services such as tissue microarrays (TMAs), immunofluorescence, in situ hybridization, microscopy and digital imaging, and laser capture microdissection (LCM) are provided for both procured human tissue and animal research tissues transferred to the Core by investigators. The Core collaborates with researchers to assist them as needed in the IRB approval process, to advise them on sample availability, and to perform special tissue collection, dissection, and processing procedures. Malignant, pre-malignant benign, diseased, and normal tissues are obtained from surgical resections and autopsies. Normal adjacent tissue and tissues from different organ sites from the same donor are also available to researchers. All work is conducted in a manner that preserves sample integrity, protects donor identity, and facilitates the minimization of disruptions to surgical operating rooms and surgical pathology units during the collection process. The Tissue Resources Core is a critical resource for projects requiring human tissues for research and services that are not easily duplicated in other laboratories, such as automated IHC;or are significantly limited when accessed through a resource such as clinical pathology laboratories of area hospitals. Members from all the research programs use the services on a large scale. Access to clinical archived FFPE tissues has high impact on research projects, since large numbers of samples with clinical annotations and outcome data may be obtained within a short period of time. In continuation of its record of contributions to the advancement of science in past years, the Tissue Resources Core facilitates the research Case CCC members conduct. Services and materials provided by the Core have assisted research in gastrointestinal, breast, female genital, hematopoietic, lung, brain and prostate cancer. During the period 2006-2012 there were >74 publications from Case CCC members in journals such as J Pathol, Prostate, Oncogene, Clin Cancer Research, Neoplasia, Int J Cancer, Cancer Epidemiol Biomarkers, and Lung Cancer.

Public Health Relevance

The Case Comprehensive Cancer Center is Northeast Ohio's only NCI designated comprehensive cancer center providing bench-to-bedside medical research involving partnerships between basic, clinical and population scientists to speed translation of laboratory discoveries into new prevention/intervention and cancer treatments.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA043703-24
Application #
8765398
Study Section
Subcommittee B - Comprehensiveness (NCI)
Project Start
Project End
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
24
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Case Western Reserve University
Department
Type
DUNS #
City
Cleveland
State
OH
Country
United States
Zip Code
44106
He, Tian; McColl, Karen; Sakre, Nneha et al. (2018) Post-transcriptional regulation of PIAS3 expression by miR-18a in malignant mesothelioma. Mol Oncol 12:2124-2135
Roche, Kathryn L; Nukui, Masatoshi; Krishna, Benjamin A et al. (2018) Selective 4-Thiouracil Labeling of RNA Transcripts within Latently Infected Cells after Infection with Human Cytomegalovirus Expressing Functional Uracil Phosphoribosyltransferase. J Virol 92:
Bedell, Hillary W; Hermann, John K; Ravikumar, Madhumitha et al. (2018) Targeting CD14 on blood derived cells improves intracortical microelectrode performance. Biomaterials 163:163-173
Nagaraj, A B; Wang, Q Q; Joseph, P et al. (2018) Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent drug candidates for cancer treatment. Oncogene 37:403-414
Somasegar, Sahana; Li, Li; Thompson, Cheryl L (2018) No association of reproductive risk factors with breast cancer tumor grade. Eur J Cancer Prev 27:140-143
Gu, Xiaorong; Ebrahem, Quteba; Mahfouz, Reda Z et al. (2018) Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates. J Clin Invest 128:4260-4279
Bosca, Federica; Bielecki, Peter A; Exner, Agata A et al. (2018) Porphyrin-Loaded Pluronic Nanobubbles: A New US-Activated Agent for Future Theranostic Applications. Bioconjug Chem 29:234-240
Benson, Bryan L; Li, Lucy; Myers, Jay T et al. (2018) Biomimetic post-capillary venule expansions for leukocyte adhesion studies. Sci Rep 8:9328
Morrow, James J; Bayles, Ian; Funnell, Alister P W et al. (2018) Positively selected enhancer elements endow osteosarcoma cells with metastatic competence. Nat Med 24:176-185
Cooper, Gregory S; Markowitz, Sanford D; Chen, Zhengyi et al. (2018) Evaluation of Patients with an Apparent False Positive Stool DNA Test: The Role of Repeat Stool DNA Testing. Dig Dis Sci 63:1449-1453

Showing the most recent 10 out of 1227 publications